Genetic Polymorphism oriented Phase II Study of Irinotecan and Doxifluridine for Unresectable or Recurrent Colorectal Cancer

ABSTRACT: Interventions: Irinotecan was infused 150 mg/m2 for pts with *1/*1 genotype and 70 mg/m2 for *1/*28. Irinotecan was infused 150 mg/m2 for pts with *1/*1 genotype and 70 mg/m2 for *1/*28. Primary outcome(s): Response rate Study Design: expanded access Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620453 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR